Medigen Vaccine Biologics Corporation (TPEX:6547)

Medigen Vaccine Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	632.12	605.64	389.62	365.04	3,281	11.51
Revenue Growth (YoY)	1.39%	55.44%	6.73%	-88.87%	28413.03%	927.41%
Cost of Revenue	244.93	209.22	159.4	577.64	975.96	3.87
Gross Profit	387.19	396.42	230.22	-212.6	2,305	7.64
Selling, General & Admin	308.62	320.58	243.44	183.67	148.21	91.96
Research & Development	209.97	221.51	1,201	1,140	1,193	679.56
Operating Expenses	518.59	542.09	1,444	1,324	1,341	771.52
Operating Income	-131.4	-145.67	-1,214	-1,536	963.73	-763.88
Interest Expense	-8.75	-18.89	-37.57	-26.89	-6.02	-16.42
Interest & Investment Income	38.24	46.25	83.28	7.61	2.74	1.48
Currency Exchange Gain (Loss)	38.35	38.35	-0.33	28.86	7.52	4.15
Other Non Operating Income (Expenses)	-79.09	-1.62	8.61	32.25	-0.07	0.19
EBT Excluding Unusual Items	-142.64	-81.57	-1,160	-1,494	967.9	-774.49
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0.06
Gain (Loss) on Sale of Assets	0.41	0.41	-	-	-	19.73
Other Unusual Items	0.7	0.7	-	19.86	442.36	80.54
Pretax Income	-141.54	-80.47	-1,160	-1,475	1,410	-674.28
Net Income	-141.54	-80.47	-1,160	-1,475	1,410	-674.28
Net Income to Common	-141.54	-80.47	-1,160	-1,475	1,410	-674.28
Shares Outstanding (Basic)	326	329	328	323	319	277
Shares Outstanding (Diluted)	326	329	328	323	321	277
Shares Change (YoY)	-1.44%	0.10%	1.50%	0.73%	15.82%	20.08%
EPS (Basic)	-0.43	-0.24	-3.53	-4.56	4.42	-2.43
EPS (Diluted)	-0.43	-0.24	-3.53	-4.56	4.39	-2.43
Free Cash Flow	-3.6	6.46	-521.25	-1,353	446.26	-689.22
Free Cash Flow Per Share	-0.01	0.02	-1.59	-4.18	1.39	-2.49
Gross Margin	61.25%	65.45%	59.09%	-58.24%	70.25%	66.36%
Operating Margin	-20.79%	-24.05%	-311.54%	-420.85%	29.37%	-6638.40%
Profit Margin	-22.39%	-13.29%	-297.68%	-403.95%	42.98%	-5859.74%
Free Cash Flow Margin	-0.57%	1.07%	-133.78%	-370.64%	13.60%	-5989.55%
EBITDA	-8.8	-26.16	-1,098	-1,423	1,072	-653.8
EBITDA Margin	-1.39%	-4.32%	-281.86%	-	32.67%	-
D&A For EBITDA	122.6	119.5	115.64	112.91	108.34	110.08
EBIT	-131.4	-145.67	-1,214	-1,536	963.73	-763.88
EBIT Margin	-20.79%	-24.05%	-	-	29.37%	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.